Catalyst Brief

← Calendar

Readoutin 14d

Teva Branded Pharmaceutical Products R&D LLC — TEV-56248

Phase 3 primary completion: A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations.

Date
Dec 2026
Type
Readout
Indication
Asthma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.